Glucophage

Primary Use

Glucophage is primarily prescribed to improve blood sugar control in patients with type 2 diabetes mellitus. It belongs to a class of drugs called biguanides and works by helping the body respond better to the insulin it produces, while also reducing the amount of sugar the liver makes and the amount of sugar the intestines absorb from food.

How It Is Used

This medication is often the first-line treatment for type 2 diabetes. It may be used in the following ways:

• Monotherapy: Used alone when diet and exercise are not enough to control blood sugar.
• Combination Therapy: Used together with other oral diabetes medications or insulin when a single drug is not sufficient.

Important Considerations

Glucophage is specifically for type 2 diabetes, a condition where the body does not use insulin normally and cannot control the amount of sugar in the blood. It is not used to treat type 1 diabetes, a condition where the body does not produce insulin at all. Proper management of blood sugar helps reduce the risk of serious complications, such as heart disease, kidney damage, nerve problems, and vision loss.

Mechanism of Action

Glucophage, which contains the active ingredient metformin, works in several ways to help manage blood sugar levels. It belongs to a class of medications called biguanides. Unlike some other diabetes medications, it does not cause the body to produce more insulin, but instead focuses on how the body handles existing sugar and insulin.

The medication primarily works through the following three methods:

• Reducing liver sugar production: It limits the amount of glucose (sugar) that the liver releases into the bloodstream.
• Improving insulin sensitivity: It helps the muscles and other tissues in the body become more sensitive to insulin, which allows them to absorb and use sugar from the blood more efficiently.
• Decreasing sugar absorption: It slows down the amount of sugar the intestines absorb from the food you eat.

Because Glucophage does not stimulate the pancreas to produce additional insulin, it is less likely to cause dangerously low blood sugar levels, known as hypoglycemia, when used as a standalone treatment.

Common Side Effects

The most frequent side effects of Glucophage involve the digestive system. These symptoms are often most noticeable when first starting the medication or when the dose is increased. Common side effects include:

• Diarrhea
• Nausea or vomiting
• Stomach pain, gas, or bloating
• Constipation
• Heartburn
• Metallic taste in the mouth
• Headache
• Muscle pain

Serious Side Effects

Some side effects can be severe and require immediate medical care. Seek emergency medical help if you experience symptoms of lactic acidosis, a rare but serious condition, which include:

• Extreme tiredness or weakness
• Unusual muscle pain
• Trouble breathing or shortness of breath
• Dizziness or lightheadedness
• Slow or irregular heartbeat
• Sudden stomach discomfort with nausea and vomiting after you have been taking the drug for a while

Other serious side effects include chest pain or signs of an allergic reaction, such as a skin rash, itching, or swelling. While Glucophage does not typically cause low blood sugar (hypoglycemia) on its own, it may occur if the medication is taken with other diabetes drugs like insulin or sulfonylureas.

Boxed Warning: Lactic Acidosis

Glucophage contains a boxed warning regarding the risk of lactic acidosis. This is a rare but serious condition characterized by the buildup of lactic acid in the bloodstream, which can be fatal if not treated. It is a medical emergency that requires immediate hospitalization.

Risk factors that increase the likelihood of developing lactic acidosis include:

• Renal Impairment: The risk increases with the severity of kidney disease.
• Age: Individuals 65 years of age or older are at higher risk.
• Radiological Studies: The use of intravascular iodinated contrast agents can lead to an acute decrease in kidney function.
• Surgery: Major surgical procedures may require temporary discontinuation of the medication.
• Hypoxic States: Conditions such as heart failure or severe infection that reduce oxygen levels in the blood.
• Alcohol Intake: Excessive acute or chronic alcohol consumption can enhance the effect of metformin on lactate metabolism.
• Hepatic Impairment: Liver disease may limit the body's ability to clear lactate.

Contraindications

Glucophage is contraindicated in individuals with the following conditions:

• Severe renal impairment (estimated glomerular filtration rate [eGFR] below 30 mL/min/1.73 m²).
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Known hypersensitivity to metformin hydrochloride.

Vitamin B12 Levels

Long-term treatment with Glucophage has been associated with a decrease in serum vitamin B12 levels in some patients. This may lead to anemia or peripheral neuropathy. Healthcare providers may recommend periodic monitoring of B12 levels and blood counts, particularly for individuals with inadequate vitamin B12 or calcium intake or absorption.

Monitoring Kidney Function

Because metformin is primarily excreted by the kidneys, the risk of accumulation and lactic acidosis increases with the degree of kidney impairment. Kidney function (eGFR) is typically assessed before starting treatment and at least annually thereafter. More frequent monitoring may be necessary for those at risk of developing renal impairment, such as the elderly.

Hypoglycemia

Glucophage generally does not cause low blood sugar (hypoglycemia) when used as a single agent. However, hypoglycemia may occur when it is used in combination with other glucose-lowering medications, such as insulin or sulfonylureas, or in cases of deficient caloric intake or strenuous exercise.

Pregnancy

Managing blood sugar levels is important during pregnancy to reduce the risk of complications for both the parent and the developing baby. Glucophage is used by some pregnant individuals to treat type 2 diabetes or gestational diabetes. While metformin crosses the placenta, current research has not established a definitive link between the medication and an increased risk of birth defects or other developmental issues. Healthcare providers typically evaluate whether to continue Glucophage or use insulin during pregnancy based on the patient's specific medical needs.

Breastfeeding

Metformin is known to pass into breast milk in small amounts. Studies suggest that the levels found in milk are low and generally considered safe for nursing infants. However, because the drug is present in breast milk, it is recommended to discuss the benefits and potential risks of breastfeeding with a healthcare professional. Monitoring the infant for any unusual symptoms is also advised when the parent is taking this medication.

Available Forms

Glucophage is provided in the following oral dosage forms:

• Oral Tablets: These are immediate-release tablets taken by mouth.
• Extended-Release Oral Tablets: These tablets are designed to release the medication slowly over a longer period.

FDA Approval and Indications

Glucophage (metformin hydrochloride) was first approved by the FDA in 1994. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The immediate-release formulation is also approved for use in pediatric patients aged 10 years and older.

Boxed Warning

The FDA requires a boxed warning for Glucophage due to the risk of metformin-associated lactic acidosis. This is a rare but serious metabolic complication that can occur if metformin builds up in the body. The risk is higher in patients with certain conditions, including:

• Severe kidney impairment
• Liver impairment
• Congestive heart failure
• Excessive alcohol intake
• Dehydration

Regulatory Updates on Kidney Function

In 2016, the FDA updated its safety communications regarding metformin use in patients with kidney disease. The agency transitioned from using serum creatinine levels to using the estimated glomerular filtration rate (eGFR) to measure kidney function. Under current regulatory guidelines, Glucophage is contraindicated in patients with an eGFR below 30 mL/min/1.73 m2. The FDA also recommends that healthcare providers evaluate the risks and benefits of starting or continuing the medication in patients with an eGFR between 30 and 45 mL/min/1.73 m2.

Safety and Monitoring

As part of its regulatory status, the FDA requires specific monitoring for patients taking Glucophage. This includes periodic assessment of kidney function and monitoring for vitamin B12 deficiency, as long-term use has been associated with a decrease in serum vitamin B12 levels.

Metformin belongs to a class of drugs called biguanides. It helps control blood sugar in three main ways:

• It reduces the amount of glucose (sugar) produced by the liver.
• It decreases the amount of sugar the body absorbs from food.
• It increases the body's sensitivity to insulin, helping cells use glucose more effectively.

Metformin is often the first-line treatment for type 2 diabetes. It is used alongside diet and exercise to improve blood sugar control. Because it does not cause the body to produce more insulin, it has a lower risk of causing low blood sugar (hypoglycemia) compared to some other diabetes medications. It is available in both immediate-release and extended-release forms and is not used to treat type 1 diabetes.